Table 4. Univariate analysis- OS of whole, localised and metastatic cohorts.

Variable	HR	CI	p value	HR	CI	p value	HR	CI	p value
	For whole cohort			For localised cohort			For metastatic cohort
Gender (male versus female)	2.59	0.34–19.7	0.35	1.32	0.16–10.6	0.78	2.84	0.33–24.4	0.3
Age (>10 years versus £10 years)	2.38	0.86–6.5	0.09	1.67	0.35–8.1	0.52	1.23	0.27–5.5	0.8
Site of primary (BP versus others)	1.12	0.4–3.1	0.8	1.12	0.4–3.1	0.8	0.92	0.2–4.2	0.9
Histology (ARMS versus ERMS)	2.9	0.6–13	0.16	-	-	-	3.38	0.03–1.81	0.2
Lymph node involvement	3.36	1.2–9.4	0.02	3.75	0.9–15.1	0.06	4.1	0.7–23.4	0.1
Group (IV versus localised)	4.46	1.65–12	0.003	-	-	-	-	-	-
Radiotherapy > 20.5 weeks from start of chemotherapy	1.01	0.27–3.8	0.98	1.07	0.2–5.3	0.93	1.22	0.1–19.8	0.89
tsize > 5 cm	2.4	0.77–7.6	0.12	3.23	0.65–15.8	0.15	0.65	0.12–3.62	0.62
tsize > 6.45 cm	4.38	1.4–13.7	0.01	6.93	1.4–34.1	0.017	0.65	0.11–3.62	0.6
Post definitive radiotherapy PET FDG-avid residual	-	-	0.009	-	-	0.009	-	-	0.6
Local therapy (RT versus surgery)	0.91	0.26–3.23	0.9	1.71	0.33–8.82	0.5	0.06	0.00–1.17	0.063